AR041061A1 - Uso de la eritropoyetina en pacientes con diabetes - Google Patents

Uso de la eritropoyetina en pacientes con diabetes

Info

Publication number
AR041061A1
AR041061A1 ARP030103092A ARP030103092A AR041061A1 AR 041061 A1 AR041061 A1 AR 041061A1 AR P030103092 A ARP030103092 A AR P030103092A AR P030103092 A ARP030103092 A AR P030103092A AR 041061 A1 AR041061 A1 AR 041061A1
Authority
AR
Argentina
Prior art keywords
erythropoietin
conjugate
protein
erythropoietin protein
kilodaltons
Prior art date
Application number
ARP030103092A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR041061A1 publication Critical patent/AR041061A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de la eritropoyetina para el tratamiento de las perturbaciones de la distribución del hierro en pacientes con diabetes. Reivindicación 10: El uso de acuerdo con la reivindicación 9, en el cual la proteína eritropoyetina es un conjugado, dicho conjugado comprende una proteína eritropoyetina que tiene por lo menos un grupo amino libre y tiene una actividad biológica in vivo de hacer que las células de la médula ósea aumenten la producción de reticulocitos y glóbulos rojos y se selecciona del grupo formado por la eritropoyetina humana y sus análogos que tienen una secuencia de la eritropoyetina humana modificada por el agregado de desde 1 hasta 6 sitios de glicosilación o un reordenamiento de por lo menos un sitio de glicosilación; dicha proteína eritropoyetina está ligada en forma covalente a grupos n poli (etilenglicol) de la fórmula -CO-(CH2)x-(OCH2CH2)m-OR o con el -CO de cada grupo poli (etilenglicol) formando un enlace de amida con uno de dichos grupos amino; en la cual R es alquilo inferior; x es 2 ó 3; m es desde aproximadamente 450 hasta aproximadamente 900; n es desde 1 hasta 3; y n y m se eligen de modo tal que el peso molecular del conjugado menos la proteína eritropoyetina es desde 20 Kilodaltons hasta 100 Kilodaltons.
ARP030103092A 2002-08-29 2003-08-27 Uso de la eritropoyetina en pacientes con diabetes AR041061A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02019100 2002-08-29

Publications (1)

Publication Number Publication Date
AR041061A1 true AR041061A1 (es) 2005-04-27

Family

ID=31970265

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103092A AR041061A1 (es) 2002-08-29 2003-08-27 Uso de la eritropoyetina en pacientes con diabetes

Country Status (15)

Country Link
US (1) US7459435B2 (es)
EP (1) EP1536823B1 (es)
JP (1) JP5128048B2 (es)
KR (1) KR20050057054A (es)
CN (1) CN1311866C (es)
AR (1) AR041061A1 (es)
AT (1) ATE510556T1 (es)
AU (1) AU2003251713B2 (es)
BR (1) BRPI0313792B8 (es)
CA (1) CA2496581C (es)
ES (1) ES2364651T3 (es)
MX (1) MXPA05002067A (es)
PL (1) PL209699B1 (es)
RU (1) RU2305554C2 (es)
WO (1) WO2004019972A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058347A1 (en) * 2003-12-19 2005-06-30 F. Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
AU2005260763B2 (en) * 2004-06-30 2011-12-22 Nektar Therapeutics Polymer-factor IX moiety conjugates
WO2006061853A2 (en) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Novel erythropoietic compounds and a process for producing erythropoietic compounds
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
JP5553506B2 (ja) * 2006-03-22 2014-07-16 中外製薬株式会社 エリスロポエチン溶液製剤
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
MX2014012625A (es) 2012-04-19 2015-05-15 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
EA033788B1 (ru) 2012-11-20 2019-11-26 Opko Biologics Ltd Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
TW201808988A (zh) 2016-07-11 2018-03-16 歐科生物製品有限公司 長效型凝血因子及其生產方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
NO881507D0 (no) * 1987-04-10 1988-04-07 Ortho Pharma Corp Fremgangsmaate for forhoeyning av hematokritnivaaet til et normalt pattedyr.
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
JPH04505104A (ja) * 1989-11-06 1992-09-10 セル　ジェネシス，インコーポレイティド 相同組換え法を用いてのタンパク質の生成
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
DE69034135T3 (de) 1989-12-22 2012-08-23 Laboratoires Serono S.A. DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5324650A (en) * 1990-03-20 1994-06-28 E. I. Du Pont De Nemours And Company Situ process for production of conjugates
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
AU1676992A (en) 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
CA2101361A1 (en) 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
ATE200030T1 (de) 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
JP2000514092A (ja) 1997-03-18 2000-10-24 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング エリトロポエチン及び鉄調製物を含む医薬的組み合わせ調製物
EP0885613A1 (de) * 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PT1311285E (pt) 2000-05-15 2005-06-30 Hoffmann La Roche Composicao farmaceutica liquida contendo um derivado de eritropoietina
US20020065214A1 (en) * 2000-11-29 2002-05-30 Adrian Iaina Method of treating congestive heart failure
CA2431964C (en) * 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
DE60223931T2 (de) 2001-09-14 2008-04-03 Roche Diagnostics Gmbh Differentialdiagnose von störungen vom eisenmetabolismus

Also Published As

Publication number Publication date
MXPA05002067A (es) 2005-06-08
PL209699B1 (pl) 2011-10-31
US20040110679A1 (en) 2004-06-10
CA2496581C (en) 2019-09-03
RU2305554C2 (ru) 2007-09-10
WO2004019972A1 (en) 2004-03-11
CN1678341A (zh) 2005-10-05
PL375784A1 (en) 2005-12-12
CN1311866C (zh) 2007-04-25
AU2003251713A1 (en) 2004-03-19
ATE510556T1 (de) 2011-06-15
JP5128048B2 (ja) 2013-01-23
EP1536823A1 (en) 2005-06-08
ES2364651T3 (es) 2011-09-08
BR0313792A (pt) 2005-07-12
EP1536823B1 (en) 2011-05-25
CA2496581A1 (en) 2004-03-11
RU2005108976A (ru) 2006-01-27
US7459435B2 (en) 2008-12-02
JP2006503821A (ja) 2006-02-02
KR20050057054A (ko) 2005-06-16
AU2003251713B2 (en) 2006-12-21
BRPI0313792B8 (pt) 2021-05-25
BRPI0313792B1 (pt) 2016-10-18

Similar Documents

Publication Publication Date Title
AR041061A1 (es) Uso de la eritropoyetina en pacientes con diabetes
CO5190661A1 (es) Derivados de la eritropoyetina
AR035407A1 (es) Conjugados de eritropoyetina, composiciones farmaceuticas que los comprenden, uso de dichos conjugados en la preparacion de medicamentos, proceso para preparar dichos conjugados y glicoproteinas de eritropoyetina
ATE505204T1 (de) Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
RU2008145084A (ru) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
BRPI0109494B8 (pt) muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
BRPI0012138B8 (pt) conjugado, composição que compreende conjugados, composição farmacêutica, uso de um conjugado ou uma composição e processo para a preparação de um conjugado ou uma composição
BRPI0811320A2 (pt) Surfactantes reconstituídos com propriedades melhoradas
RU2005119649A (ru) Новое применение эритропоэтина при сердечных заболеваниях
EA200000379A1 (ru) Усеченные по амино-концу rantes как антагонисты хемокинов
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
TW200727911A (en) Treatment of neurodegenerative disorders
DE602004028239D1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
AR034853A1 (es) Secuencia de acido nucleico sintetico que codifica una alfa-galactosidasa, vector y celula que la comprenden, metodo para producir alfa-galactosidasa, metodo para prepararla, composicion farmaceutica que comprende dicha secuencia y su uso para preparar esta ultima
JO2257B1 (en) Erythropoietin derivatives
ECSP003557A (es) Derivados de eritropoyetina
CN114025846A (zh) 用于治疗关节疾病的药物组合物及其制备方法
UY26229A1 (es) Derivados de la eritopoyetina
WO2005087809B1 (en) Peptides from vitronectin and their therapeutic exploitation for osteoblast adhesion
Zahn How Insulin Came from Heidelberg to Aachen and Why it Took Five Years
TH62376A (th) Peg คอนจูเกตของ hgf-nk4
TH52291B (th) อนุพันธ์อีริโทรโพอีทิน

Legal Events

Date Code Title Description
FA Abandonment or withdrawal